The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Xu Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: lixu@ahmu.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Protein Serine-Threonine Kinases, Transcription Factors, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
The prevailing view in the cancer field is that Hippo (Hpo) signaling pathway functions as a tumor suppressor pathway by blocking the oncogenic potential of the pathway effectors Yes1-associated transcriptional regulator (YAP)/transcriptional coactivator with PDZ-binding motif. However, YAP can also function as a context-dependent tumor suppressor in several types of cancer including clear cell renal cell carcinomas (ccRCCs). We find that, in addition to inhibiting hypoxia-inducible factor 2α, a major oncogenic driver in Von Hippel-Lindau-/- ccRCC, YAP also blocks nuclear factor κB (NF-κB) signaling in ccRCC to inhibit cancer cell growth under conditions where hypoxia-inducible factor 2α is dispensable. Mechanistically, YAP inhibits the expression of Zinc fingers and homeoboxes 2 (ZHX2), a Von Hippel-Lindau substrate and critical cofactor of NF-κB in ccRCC. Furthermore, YAP competes with ZHX2 for binding to the NF-κB subunit p65. Consequently, elevated nuclear YAP blocks the cooperativity between ZHX2 and the NF-κB subunit p65, leading to diminished NF-κB target gene expression. Pharmacological inhibition of Hpo kinase blocked NF-κB transcriptional program and suppressed ccRCC cell growth, which can be rescued by overexpression of ZHX2 or p65. Our study uncovers a crosstalk between the Hpo and NF-κB/ZHX2 pathways and its involvement in ccRCC growth inhibition, suggesting that targeting the Hpo pathway may provide a therapeutical opportunity for ccRCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: lixu@ahmu.edu.cn.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Math and Sciences, Tarrant County College-NE Campus, Hurst, Texas, USA.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Boston, Massachusetts, USA; Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address:…
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health National Cancer Institute
- Welch Foundation
- National Institutes of Health
- NIH National Institute of General Medical Sciences
Zitieren
APA
Li, X., Cho, Y. S., Han, Y., Zhou, M., Liu, Y., Yang, Y., Zhuo, S., & Jiang, J. (2025). The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108430
Vancouver
Li X, Cho YS, Han Y, Zhou M, Liu Y, Yang Y, et al. The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108430
BibTeX
@article{Li2025,
author = {Li, Xu and Cho, Yong Suk and Han, Yuhong and Zhou, Mengmeng and Liu, Yuchen and Yang, Yingzi and Zhuo, Shu and Jiang, Jin},
title = {The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108430}
}
EUVIMED